Cited by 293Thyroid Disorders and TreatmentsEstrogen and related hormone effectsThyroid Cancer Diagnosis and Treatment

Paradigms of dynamic control of thyroid hormone signaling

Open access
Bianco, Antonio C, Dumitrescu, Alexandra, Gereben, Balázs, Ribeiro, Miriam O, Fonseca, Tatiana L, Fernandes, Gustavo W, Bocco, Barbara M L C·2019·Endocrine Reviews

Abstract

Thyroid hormone (TH) molecules enter cells via membrane transporters and, depending on the cell type, can be activated (i.e., T4 to T3 conversion) or inactivated (i.e., T3 to 3,3'-diiodo-l-thyronine or T4 to reverse T3 conversion). These reactions are catalyzed by the deiodinases. The biologically active hormone, T3, eventually binds to intracellular TH receptors (TRs), TRα and TRβ, and initiate TH signaling, that is, regulation of target genes and other metabolic pathways. At least three families of transmembrane transporters, MCT, OATP, and LAT, facilitate the entry of TH into cells, which follow the gradient of free hormone between the extracellular fluid and the cytoplasm. Inactivation or marked downregulation of TH transporters can dampen TH signaling. At the same time, dynamic modifications in the expression or activity of TRs and transcriptional coregulators can affect positively or negatively the intensity of TH signaling. However, the deiodinases are the element that provides greatest amplitude in dynamic control of TH signaling. Cells that express the activating deiodinase DIO2 can rapidly enhance TH signaling due to intracellular buildup of T3. In contrast, TH signaling is dampened in cells that express the inactivating deiodinase DIO3. This explains how THs can regulate pathways in development, metabolism, and growth, despite rather stable levels in the circulation. As a consequence, TH signaling is unique for each cell (tissue or organ), depending on circulating TH levels and on the exclusive blend of transporters, deiodinases, and TRs present in each cell. In this review we explore the key mechanisms underlying customization of TH signaling during development, in health and in disease states.

Integrity signals

Registry

Crossref · 10.1210/er.2018-00275

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • T3 represses gene transcription of DIO2, forming a negative feedback loop to keep intracellular T3 within a range.

    “T3 can repress the gene transcription of DIO2, the primary activating enzyme that converts T4 into T3, therefore forming a negative feedback loop to keep intracellular T3 within a range (30–32).”
  • The deiodination pathway is predominantly via type 2 deiodinase (D2), which is accelerated during hypothyroidism and suppressed during hyperthyroidism.

    “The deiodination pathway is predominantly via the type 2 deiodinase (D2), which tends to play a homeostatic role, that is it is accelerated during hypothyroidism and is suppressed during hyperthyroidism (33,34).”

The citation lists haven’t been fetched yet

References 551 · Cited by 293

Authors
Bianco, A. C., Dumitrescu, A., Gereben, B., Ribeiro, M. O., Fonseca, T. L., Fernandes, G. W., & Bocco, B. M. L. C.
Affiliations
  • University of Chicago Medical Center (US)
  • HUN-REN Institute of Experimental Medicine (HU)
  • Universidade Presbiteriana Mackenzie (BR)
  • Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Medical Center, Chicago, Illinois
Corresponding author
Bianco, Antonio C
Venue
Endocrine Reviews
Published
2019-04-29
Volume
40
Issue
4
Pages
1000-1047
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2943182825
Cited by
293
References
551
Citations by year
2026: 32 · 2025: 49 · 2024: 42 · 2023: 38 · 2022: 57 · 2021: 40 · 2020: 26 · 2019: 8 · 2018: 1
FWCI
5.05
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (DK65055)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
thyroid hormone signaling, thyroid hormone transporters, deiodinases, DIO2, DIO3, T4 to T3 conversion, thyroid hormone receptor, TRα, thyroid hormone receptor beta, transcriptional coregulators, OATP transporters, thyroid hormone metabolism
MeSH terms
Animals, Female, Humans, Iodide Peroxidase, Male, Receptors, Thyroid Hormone, Thyroid Hormones, Signal Transduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review